Cargando…
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
PURPOSE: Oesophageal squamous cell carcinoma (ESCC) has a poor prognosis. Advanced tumours are treated with fluoropyrimidine/platinum chemotherapy followed by irinotecan or taxane monotherapy, but resistance is common and new treatments are needed. Approximately 20% of ESCCs carry copy number gain (...
Autores principales: | Meemanage, Madusha, Spender, Lindsay C., Collinson, Diane, Iannetta, Joanna, Challapalli, Pranavi, Turbitt, Julie, Clark, Caroline, Baxter, Mark, Murray, Graeme, Walsh, Shaun, Miedzybrodzka, Zofia, Petty, Russell D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889538/ https://www.ncbi.nlm.nih.gov/pubmed/33169187 http://dx.doi.org/10.1007/s00280-020-04187-w |
Ejemplares similares
-
Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
por: Baxter, Mark A., et al.
Publicado: (2020) -
Where technology succeeds and fails in education
por: Wong, Kevin, et al.
Publicado: (2021) -
Fail better: design smart mistakes and succeed sooner
por: Sastry, Anjali, et al.
Publicado: (2015) -
Why startups fail: and how yours can succeed
por: Feinleib, David
Publicado: (2012) -
Nuance: why some leaders succeed and others fail
por: Fullan, Michael
Publicado: (2018)